MetMAb Articles
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
Showing 1-3 of 3 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
